# EXPLORE-RCC (NCT06794229)

> Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

No report yet. It can be ordered.

- Drugs tested: zanzalintinib plus nivolumab
- Indication: locally advanced/inoperable clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06794229
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Qian Qin
- Conditions: Locally Advanced Renal Cell Carcinoma
- Interventions: Zanzalintinib; Nivolumab
- Enrollment: 69
- Primary outcome: Objective response rate (ORR)

## Indexed commentary on EXPLORE-RCC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=explore-rcc-nct06794229